SpyBiotech Announces the Completion of Enrollment in Phase I Trial of SPYVLP01 Targeting Human Cytomegalovirus (HCMV)

Source :: Business Wire. July 23, 2024
Publication Year :: 2024
Abstract: OXFORD, England & CAMBRIDGE, Mass. -- SpyBiotech, a biotechnology company with a novel vaccine platform technology that can target infectious diseases, cancer, and chronic diseases, announced today the completion of [...]

Subjects :: Biological products industry -- Product development
Medical research
Medicine, Experimental
Communicable diseases
Chronic diseases
Cytomegalovirus infections
Hepatitis B
Clinical trials
Vaccines -- Product development
Business
Business, international
University of Oxford

Tools